Rick Kaplan, Professor, Senior Clinical Scientist
Rick Kaplan is a medical oncologist with over 30 years experience in clinical research in the USA and before settling in the UK was Chief of the Clinical Investigations Branch, National Cancer Institute, National Institutes of Health. He was Program Director for the NCI’s national program of Cooperative Groups for clinical trials of cancer treatments, and Program Director for NCI’s Brain Tumor Consortia. He was responsible for scientific coordination of NCI-funded or sponsored treatment trials in gastrointestinal, urological and brain malignancies, and has served on advisory committees and panels for NCI, NIH, FDA and for other government agencies and professional organizations, as well as for clinical trials organisations in North America, Europe and Australia.
In 2004 he came to the UK to become Associate Director for Industry for NCRN and Professor of Oncology in the Leeds Institute of Molecular Medicine. A major focus of his effort has been toward promoting collaborative research, both commercial and academic investigator led, between the NHS and companies in the pharmaceutical, biotechnology, and device industries.
He joined the MRC CTU on a part-time basis in 2008, working within the areas of colorectal, prostate, and renal cancer trials. From 2011, he has been based full time at the CTU and also works as Honorary Consultant in Oncology at University College London Hospital.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New Response Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (version 1.1). Eur J Cancer 45:228-247, 2009, doi:10.1016/j.ejca.2008.10.026; PMID: 19097774
Adams R, Meade A, Seymour M, Wilson R, Madi A, Fisher D, Kenny S, Kaye E, Hodgkinson E, Rogers P, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy J, Kaplan R, Maughan TS. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy in the first-line treatment of patients with advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncology12(7): 642–53,2011 doi:10.1016/S1470-2045(11)70102-4;PMID: 21641867
Stead M, Cameron D, Lester N, Parmar M, Haward R, Kaplan R, Maughan T, Wilson R, Campbell H, Hamilton R, Stewart D, O’Toole L, Kerr D, Potts V, Moser R, Darbyshire J, Selby P. Strengthening clinical cancer research in the United Kingdom. British Journal of Cancer 104, 1529 – 34, 2011 [doi:10.1038/bjc.2011.69; PMID: 21364584]
Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M. Evaluating many treatments and biomarkers in oncology: a new design. J Clinical Oncol 31(36):4562-68, 2013 [doi: 10.1200/JCO.2013.50.7905, 18 Nov2013; PMID: 24248692]
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, . . . Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. The Lancet 389:815-22, 2017 [doi:10.1016/S0140-6736(16)32401-1; PMID: 28110982]